AlphaStocks

ABBV vs EXEL

As of Sep 20, 2026, AbbVie (ABBV) scores 7.8/10 and Exelixis (EXEL) 6.4/10 on AlphaStocks' five-model composite, so ABBV scores higher. ABBV trades 102% above its model fair value; EXEL trades 5% below its model fair value.

ABBV

AbbVie Inc.

7.8

Strong Buy

$263.86

EXEL

EXELIXIS, INC.

6.4

Consider Buy

$58.35

ABBV vs EXEL: Which is the Better Investment?

AbbVie Inc. (ABBV) scores 7.8/10 while EXELIXIS, INC. (EXEL) scores 6.4/10 on AlphaStocks' composite model. AbbVie Inc. has the higher composite rating of Strong Buy. On a P/E basis, EXELIXIS, INC. trades at 21.0x, making it the more attractively priced of the two. EXELIXIS, INC. trades further below its estimated fair value.

This comparison is algorithmically generated and is not financial advice.

MetricABBVEXEL
Scores & Fundamentals
Composite Score7.8/106.4/10
RatingStrong BuyConsider Buy
Price$263.86$58.35
P/E Ratio110.721.0
ROE-143.0%34.8%
Market Cap$468B$16B
Fair Value$130.53$61.56
Dividend Yield2.7%
Sector Rank#2 of 168#34 of 168
Model Verdicts
PiotroskiStrongStrong
BuffettStrongAttractive
GrahamNeutralCaution
LynchNeutralAttractive
GreenblattNeutralLimited Data
View full ABBVanalysis →View full EXELanalysis →

Related comparisons

Compare any two stocks →

ABBV vs EXEL: Which Stock Scores Higher?

AbbVie Inc. (ABBV) and EXELIXIS, INC. (EXEL) are both in the Health Care sector. ABBV currently leads with a composite score of 7.8/10 (Strong Buy) compared to EXEL's 6.4/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer